Plaintiffs in two major wings of the growing litigation over the diabetes drug Invokana are seeking to consolidate the action at the federal and state court level.
Plaintiffs with claims pending in the Philadelphia Court of Common Pleas filed a petition with the court Sept. 23 seeking to consolidate their claims into a mass tort program. The move came less than a week after a New York attorney filed a motion with the U.S. Judicial Panel on Multidistrict Litigation asking that body to consolidate federal claims in the Trenton Division of the U.S. District Court of the District of New Jersey.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
